Auterion to Equip Ukraine with 33,000 AI-Powered Drone Guidance Kits Auterion’s commitment to supply Ukraine with 33,000 AI-powered drone guidance kits marks a significant development in the ongoing conflict. This...
Tariff-Fueled Inflation Impacts Lower-Income Spending – Morgan Stanley Analysis Morgan Stanley analysts warn that tariff-related inflation is disproportionately affecting lower-income households, potentially impacting consumer spending and overall economic growth. This...
Alliance Global Partners Initiates Almonty Industries With a Buy Rating, Citing Strategic Tungsten Supply Position Alliance Global Partners has initiated coverage of Almonty Industries, a tungsten mining company, with a...
Cantor Fitzgerald Reaffirms Overweight Rating on Aurora Innovation Stock Cantor Fitzgerald analysts have maintained their optimistic outlook on Aurora Innovation, reiterating an “Overweight” rating on the autonomous driving technology company’s...
Joby Aviation Stock Rating Remains Neutral at Cantor Fitzgerald Cantor Fitzgerald has maintained its Neutral rating on Joby Aviation stock. While no price target adjustment was announced in this specific...
Lucid Stock Unmoved as Cantor Fitzgerald Maintains Neutral Rating Electric vehicle (EV) manufacturer Lucid Group saw no significant change in its stock price following Cantor Fitzgerald’s decision to reiterate its...
TD Cowen Upgrades PagerDuty Stock on Potential Acquisition Buzz TD Cowen has upgraded PagerDuty’s stock, fueling speculation about a potential acquisition of the digital operations management platform. This upgrade has...
Enanta Pharmaceuticals Earns Buy Rating from H.C. Wainwright H.C. Wainwright has initiated coverage of Enanta Pharmaceuticals with a Buy rating, signaling potential upside for the biotech company. This positive assessment...
CleanSpark Stock Receives a “Buy” Rating from Ladenburg Thalmann on Growth Outlook CleanSpark ($CLSK), a bitcoin mining company, has been initiated with a “Buy” rating by Ladenburg Thalmann, citing a...
H.C. Wainwright Maintains Sell Rating on Sarepta Therapeutics, Sets Target Price at $0 H.C. Wainwright analysts have reiterated their Sell rating on Sarepta Therapeutics stock, maintaining a target price of...
